{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(4)"],"submitter":["Xing J"],"pubmed_abstract":["Buparlisib is a highly efficient and selective PI3K inhibitor and a member of the 2,6-dimorpholinopyrimidine-derived family of compounds. It selectively inhibits four isomers of PI3K, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, by competitively binding the lipid kinase domain on adenosine 5'-triphosphate (ATP), and serves an important role in inhibiting proliferation, promoting apoptosis and blocking angiogenesis, predominantly by antagonizing the PI3K/AKT pathway. Buparlisib has been confirmed to have a clinical effect in patients with solid tumors and hematological malignancies. A global, phase II clinical trial with buparlisib and paclitaxel in head and neck squamous cell carcinoma has now been completed, with a manageable safety profile. Buparlisib currently has fast-track status with the United St"],"journal":["Oncology letters"],"pagination":["266"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7885152"],"repository":["biostudies-literature"],"pubmed_title":["Research update on the anticancer effects of buparlisib."],"pmcid":["PMC7885152"],"pubmed_authors":["Yi J","Xing J","Yang J","Gu Y"],"additional_accession":[]},"is_claimable":false,"name":"Research update on the anticancer effects of buparlisib.","description":"Buparlisib is a highly efficient and selective PI3K inhibitor and a member of the 2,6-dimorpholinopyrimidine-derived family of compounds. It selectively inhibits four isomers of PI3K, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, by competitively binding the lipid kinase domain on adenosine 5'-triphosphate (ATP), and serves an important role in inhibiting proliferation, promoting apoptosis and blocking angiogenesis, predominantly by antagonizing the PI3K/AKT pathway. Buparlisib has been confirmed to have a clinical effect in patients with solid tumors and hematological malignancies. A global, phase II clinical trial with buparlisib and paclitaxel in head and neck squamous cell carcinoma has now been completed, with a manageable safety profile. Buparlisib currently has fast-track status with the United St","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-06-01T00:35:17.694Z","creation":"2025-06-01T00:35:17.694Z"},"accession":"S-EPMC7885152","cross_references":{"pubmed":["33717263"],"doi":["10.3892/ol.2021.12527"]}}